Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) EBITDA Margin: 2013-2017

Historic EBITDA Margin for Soleno Therapeutics (SLNO) over the last 3 years, with Jun 2017 value amounting to -296,800.00%.

  • Soleno Therapeutics' EBITDA Margin fell 18205000.00% to -296,800.00% in Q2 2017 from the same period last year, while for Jun 2017 it was -926.52%, marking a year-over-year increase of 48662.00%. This contributed to the annual value of 75,969.26% for FY2024, which is N/A change from last year.
  • As of Q2 2017, Soleno Therapeutics' EBITDA Margin stood at -296,800.00%, which was down 57,184.78% from -518.11% recorded in Q1 2017.
  • Soleno Therapeutics' 5-year EBITDA Margin high stood at 195.07% for Q2 2014, and its period low was -296,800.00% during Q2 2017.
  • Its 3-year average for EBITDA Margin is -43,117.22%, with a median of -1,370.45% in 2015.
  • As far as peak fluctuations go, Soleno Therapeutics' EBITDA Margin surged by 1,007,358bps in 2016, and later tumbled by 18,205,000bps in 2017.
  • Over the past 5 years, Soleno Therapeutics' EBITDA Margin (Quarterly) stood at 180.42% in 2013, then plummeted by 10,088bps to 79.54% in 2014, then crashed by 153,178bps to -1,452.24% in 2015, then skyrocketed by 80,629bps to -645.95% in 2016, then crashed by 18,205,000bps to -296,800.00% in 2017.
  • Its EBITDA Margin stands at -296,800.00% for Q2 2017, versus -518.11% for Q1 2017 and -645.95% for Q4 2016.